Topics / Immunology
Weekly issue
Immunology Papers of the Week
The top Immunology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.
- 1Glycosylation of The Premembrane Protein Is Required for Dengue Virus Replication in Both C6/36 and Vero Cells
In this manuscript, we investigated the importance of the N69 glycosylation site by generating both DENV2 and DENV4 loss-of-function viruses.
- 2
- 3Repurposed Endogenous Virus-like Vesicles Mediate Dendritic Cell Long-range Antigen Presentation and T Cell Activation for Enhanced Cancer Vaccination
Here we show that dendritic cells repurpose the virus-like retrotransposon-derived Arc gene to generate endogenous virus-like vesicles (VLVs) that predominantly carry peptide-MHC and high-density co-stimulatory ligands, intensifying and extending antigen presentation.
- 4Efficacy and Safety of Obinutuzumab Β in Patients with Active Systemic Lupus Erythematosus: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial
People with lived experience were not involved as research partners in this study.
- 5The Transformation of Oncology Drug Development in China: Toward A New Phase of Innovation
We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies.
Get papers like these the day they come out, not a week later.
Follow this category- 6Pancreatic Α Cells Function As MHC Class II-dependent Antigen-presenting Cells in Type 1 Diabetes
Here, we show that pancreatic α cells acquire major histocompatibility complex (MHC) class II (MHC-II)-dependent antigen-presenting capacity during T1D progression.
- 7Dupilumab Modulates Type II IL-4/IL-13 Receptor-expressing Immune Cells in Eosinophilic Chronic Rhinosinusitis
To define the cell type-specific effects of dupilumab in eCRS, we examined IL-4/IL-13 receptor-dependent transcriptional responses in tissue-resident immune cells.
- 8Mechanosensitive YAP-RUNX1 Signaling Drives T H 1 Cell Dysfunction and Tumor Immunosuppression
Here we show that elevated tissue stiffness subverts tumor-infiltrating type 1 helper T (T 1) cells to drive immunosuppression in pancreatic cancer.
- 9Impact of Venetoclax-based Therapies on CLL-associated Autoimmune Cytopenias: A Retrospective Study Conducted By ERIC
This study aimed to evaluate preexisting and treatment-emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax-based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti-CD20 monoclonal antibodies and/or BTK inhibitors).
- 10Self-amplifying RNA Vaccines Encoding Chimeric and Mosaic Hemagglutinins Confer Immunity Against Phylogenetically Diverse Influenza A Viruses
Here, we evaluate self-amplifying mRNA (samRNA) vaccines encoding chimeric (cHA) and mosaic (mHA) hemagglutinins representing influenza A virus HA phylogenetic groups 1 and 2.
- 11
- 12AAV-mediated Expression of A SARS-CoV-2 Neutralizing Antibody in Monocyte-derived Dendritic Cells and Human Airway Epithelial Cells
Here we evaluated adeno-associated virus (AAV) vectors to enable full mAb expression in human respiratory cell subsets.
- 13Venousization Enables Angiogenesis in The Absence of VEGFR Signalling
Here we used iFlpMosaics and iSuRe-HadCre to induce and track genetic mosaics of endothelial cells (ECs) lacking VEGFR2 during the entire embryonic and postnatal development.
- 14
- 15Cancer-specific T Cell Receptor Discovery Using 150,000 Clinical Genomics Samples
Here, we identified public TCRs against therapeutically relevant targets via computational analysis of large-scale bulk RNA sequencing data obtained from routine clinical genomics testing.
- 16Reimagining COPD Treatment: Are Biologics The Next Frontier?
Growing recognition of disease heterogeneity such as a distinct type-2/eosinophilic endotype as well as advances in biologic agents motivate reassessment of monoclonal antibodies (mAbs) as targeted treatments. This narrative review summarizes evidence from Phase 2 and 3 studies for mAbs in COPD, grouping agents by molecular targets (IL-1β, IL-4/IL-4 Rα/IL-13, IL-5/IL-5 Rα, IL-8, IL-17, IL-33/ST2/RAGE/EGFR, TSLP, TNF-α).
- 17
- 18Safety, Tolerability, and Efficacy of Bepranemab in People Living with Prodromal-to-mild Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial
We aimed to investigate the safety and efficacy of bepranemab in slowing progression of tau pathology and clinical decline in people with prodromal-to-mild Alzheimer's disease.
- 19Therapeutic Landscape of Folate Receptor-α Targeting: Platforms, Progress, and Clinical Translation
By synthesizing clinical and translational insights, this review uniquely addresses the gap by bringing together major FRα-targeted strategies within a single framework, positioning clinical trials as the organizing backbone while integrating biological and engineering insights to explain observed outcomes of FRα as both a biomarker and a therapeutic axis in oncology.
- 20Is Atherosclerosis An Autoimmune Disease?
Additional contributors include dendritic cell-mediated antigen presentation, activation of the NLRP3 inflammasome and interleukin-1β signaling pathway, and type I interferon responses, all of which amplify vascular inflammation and plaque progression.